Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.84 |
| ▸ | EGFR | P00533 | 9/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.84 |
| ▸ | FLT1 | P17948 | 7/20 | 0.84 |
| ▸ | FLT4 | P35916 | 6/20 | 0.84 |
| ▸ | SRC | P12931 | 9/20 | 0.78 |
| ▸ | RET | P07949 | 2/20 | 0.71 |
| ▸ | CIT | O14578 | 1/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.71 |
| ▸ | STK17B | O94768 | 1/20 | 0.71 |
| ▸ | STK10 | O94804 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7867160 | 0.92 | KDR (0.83) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL7866060 | 0.92 | KDR (0.84) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL7857964 | 0.92 | KDR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL22997455 | 0.91 | KDR (0.81) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL7870593 | 0.91 | KDR (0.98) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL7867735 | 0.89 | KDR (0.78) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL7866019 | 0.89 | KDR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL7859597 | 0.89 | KDR (0.77) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL28424819 | 0.89 | SRC (0.85) | KDREGFRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL7864803 | 0.88 | KDR (0.98) | KDREGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2013-01-03 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110262436-A1 | TREATMENT METHOD | GENENTECH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-1853300-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | Genentech, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006089015-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | KDR 50/4885EGFR 1/4885FGFR1 1140/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885EGFR 2/4885FGFR1 47/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | KDR 50/4885EGFR 1/4885FGFR1 1140/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | KDR 34/4885EGFR 2/4885FGFR1 47/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885EGFR 2/4885FGFR1 19/4885 |
| US-20110262436-A1 | TREATMENT METHOD | HGF, HDGF, FGF2 | KDR 424/4885EGFR 6/4885FGFR1 14/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885EGFR 2/4885FGFR1 19/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | KDR 395/4885EGFR 129/4885FGFR1 462/4885 |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NOD2, RIPK2, RIPK1 | KDR 3236/4885EGFR 2498/4885FGFR1 2253/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885EGFR 2/4885FGFR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.